Enclomiphene Citrate Safety in Adolescents Ages 12 to 17

What enclomiphene citrate is, and why it comes up in adolescent care

Enclomiphene citrate is the trans-isomer of clomiphene citrate, the drug marketed for decades as Clomid for ovulation induction. Clomiphene citrate as dispensed is a mixture of two isomers, trans-enclomiphene and cis-zuclomiphene; enclomiphene alone is the more estrogen-receptor-antagonist-selective component, and it clears the body faster than the mixture. Enclomiphene is not FDA-approved as a standalone product for any indication or age group. It exists in US practice only as a compounded preparation, most often prescribed off-label to adult men with low testosterone from pituitary or hypothalamic dysfunction (secondary hypogonadism) who want to avoid the fertility-suppressing effects of testosterone replacement [2, 3].

Mechanistically, enclomiphene blocks estrogen receptors in the hypothalamus. That removes negative feedback on the pituitary, so LH and FSH rise, and the testes respond by producing more testosterone on their own. This is fundamentally different from testosterone replacement, which supplies the hormone directly and, in doing so, suppresses the body's own LH and FSH output and, with it, sperm production.

In adolescents aged 12 to 17, the only plausible clinical scenario resembles the adult one: a patient with confirmed secondary hypogonadism (low testosterone with low or inappropriately normal LH and FSH), most commonly framed as constitutional delay of growth and puberty. Standard, guideline-endorsed management of constitutional delay already exists in the form of short courses of low-dose testosterone enanthate, which the Endocrine Society's 2018 clinical practice guideline on male hypogonadism addresses for adults and which pediatric endocrinology practice has adapted for delayed puberty [1]. That guideline does not evaluate enclomiphene or any selective estrogen receptor modulator in adolescents, and no comparable guideline does. Any adolescent use of enclomiphene sits outside endorsed pathways and should be understood as an off-label extrapolation from adult data, not an application of an established pediatric protocol.

What the evidence actually shows, and where it stops

No randomized controlled trial has enrolled participants under 18 for enclomiphene citrate. The strongest human evidence is Kim and colleagues' trial in adult men with secondary hypogonadism, which found that oral enclomiphene raised testosterone and preserved sperm concentration over three months, while a comparison group on topical testosterone gel saw a large decline in sperm concentration [2]. The original manufacturer, Repros Therapeutics, ran Phase III trials (ZA-201 and ZA-301) that formed the basis of an FDA new drug application (NDA 022496); those trials enrolled adult men only, and the FDA did not approve the application in the form submitted, so no branded enclomiphene product exists on the US market as of mid-2025 [3]. That regulatory history means there is no FDA label, no FDA-reviewed dosing, and no FDA safety monitoring requirement for enclomiphene in any age group, adolescent included.

Clomiphene citrate, the parent racemic compound, has a longer and more scattered history of off-label use in adolescent males with delayed puberty or hypogonadotropic hypogonadism, but that literature is old, small, and does not report long-term outcomes on final adult height or bone density. It should not be read as adolescent safety data for enclomiphene specifically, because enclomiphene's pharmacology (higher estrogen-antagonist selectivity, faster clearance, absence of the more estrogenic zuclomiphene isomer) differs enough from the racemic mixture that adult clomiphene data and adult enclomiphene data are not interchangeable, and neither substitutes for adolescent-specific study in either compound.

Adolescent Enclomiphene Decision Framework

This framework organizes the handful of facts that should actually change a prescribing decision in a patient aged 12 to 17. It does not replace specialist evaluation; it structures what that evaluation needs to establish.

Step 1: Confirm the diagnosis is real secondary hypogonadism, not delayed puberty that will resolve on its own. Two morning total testosterone measurements below the lab's hypogonadal threshold, with LH and FSH low or inappropriately normal, plus thyroid function and prolactin checked to rule out other causes of delayed puberty [1]. If this is not confirmed, enclomiphene is not indicated regardless of age.

Step 2: Check whether a guideline-endorsed alternative has been tried first. Short-course, low-dose testosterone enanthate has an established track record in constitutional delay of growth and puberty. If that option has not been considered or discussed, enclomiphene should not be the first off-label step.

Step 3: Screen out absolute stop conditions. Do not proceed if any of the following apply: bone age more than roughly two years behind chronological age (meaning substantial linear growth potential remains and the risk-benefit math shifts), untreated hyperprolactinemia or a pituitary mass, a personal history of seizure disorder (clomiphene-class agents may lower seizure threshold, per the clomiphene label) [9], or an inability to attend monitoring visits roughly every three months.

Step 4: Weigh the one genuine adolescent-specific advantage against the two genuine adolescent-specific unknowns. The advantage: unlike exogenous testosterone, enclomiphene does not suppress the body's own LH and FSH, so it does not shut down endogenous sperm production the way testosterone replacement does in adults [2]. For a teenager with fertility as a stated future priority, that is a real reason to prefer it over testosterone. The unknowns: whether accelerating endogenous testosterone (and downstream estradiol) during active bone-plate growth measurably shortens final height in a given patient, and whether stimulating a still-maturing hypothalamic-pituitary-gonadal axis has effects that outlast the drug. Neither unknown has adolescent trial data to resolve it.

Step 5: If proceeding, set the exit criteria before the first dose. Define in writing: the testosterone target (favor the lower end of adult reference ranges rather than adult-peak targets, given axis immaturity), the monitoring interval (no less than every three months), and the specific findings that trigger discontinuation (bone-age advance beyond what the pediatric endocrinologist judges acceptable for that patient, new or worsening depressive symptoms, new visual symptoms, or testosterone rising well above the target range). A trial without a predefined stopping point is not an acceptable structure for this age group.

Growth plates: what is established and what is not

Sex steroids, and estrogen in particular, drive epiphyseal (growth plate) fusion. This is well established general endocrine physiology, documented in reviews of estrogen and androgen action on the skeleton [5]. Enclomiphene's mechanism (blocking estrogen receptors at the hypothalamus) raises LH and FSH, which raises testicular testosterone output, and peripheral tissue converts some of that testosterone to estradiol via aromatase. The net effect on systemic estradiol, and therefore on bone-age progression, has not been measured in adolescents taking enclomiphene. Extrapolating a specific estradiol threshold at which fusion accelerates would overstate what the literature supports for this population; the honest statement is that the mechanism for concern is real, the magnitude in a developing adolescent on enclomiphene specifically is not established, and bone-age monitoring is the only way to catch a problem before it becomes irreversible.

A left-hand and wrist bone-age radiograph, read against a standard atlas, at baseline and at intervals no longer than three to six months, is the practical safeguard used in pediatric endocrinology when any sex-steroid-modulating treatment is given to a patient with open growth plates [6]. Height velocity tracked with a calibrated stadiometer provides a second, complementary signal.

The developing hormonal axis and the developing brain

The hypothalamic-pituitary-gonadal axis in early-to-mid puberty is still establishing its adult pulse pattern of GnRH release. Introducing a drug that alters estrogen feedback at the hypothalamus during that calibration period is a plausible, mechanistically reasonable concern, but there is no adolescent human data, and no animal data cited in the sources reviewed for this article, that directly tests enclomiphene or a comparable SERM in a prepubertal or peripubertal system. That gap should be stated plainly rather than filled with extrapolated animal findings that were not actually about this drug or this developmental window.

Similarly, the adolescent brain continues active structural development, including regions relevant to mood regulation, into the mid-twenties [8]. Estrogen receptors are expressed in the central nervous system, and the clomiphene citrate label lists mood change, depression, and visual disturbance among reported adverse reactions in the populations it was studied in [9]. Whether adolescents experience these effects at a different rate than adults has not been established for enclomiphene; it is a reasonable basis for closer monitoring, not for a specific numeric risk estimate.

Spermatogenesis: a genuine reason some clinicians consider it, with a real caveat

The clearest adolescent-relevant advantage of enclomiphene over testosterone replacement is that it preserves the body's own gonadotropin drive, and therefore sperm production, whereas exogenous testosterone suppresses it. Kim et al. reported preserved or improved sperm concentration on enclomiphene versus a substantial decline on testosterone gel in adult men [2]. For an adolescent male where future fertility is a stated concern, this is a legitimate factor in choosing enclomiphene over testosterone, if treatment is going to happen at all.

The caveat: Sertoli cell number, which sets a lifetime ceiling on sperm production, is established during early puberty. Whether raising endogenous FSH earlier in that process (via enclomiphene) helps, harms, or has no effect on that ceiling in a general adolescent hypogonadism population is not established by controlled human data. Observational work in hypogonadotropic males treated with gonadotropins suggests earlier FSH exposure may be favorable for later testicular function, but that evidence involves direct gonadotropin therapy, not enclomiphene-induced endogenous FSH, and any specific numbers from small case series should be treated as hypothesis-generating rather than a settled dose-response finding [11]. A reproductive urologist or pediatric-experienced reproductive endocrinologist should be part of this discussion whenever fertility preservation is the stated reason for choosing enclomiphene.

Dosing: there is no adolescent protocol

There is no published, evidence-based adolescent dosing regimen for enclomiphene. Adult trials used 12.5 mg or 25 mg orally once daily [2, 3]. Simple weight-based extrapolation is not pharmacologically sound here because the drug's action depends on receptor occupancy at the hypothalamus, not on a straightforward clearance-by-weight relationship.

Clinicians who choose to proceed in an adolescent, after specialist evaluation, typically start well below the adult range and titrate slowly based on repeated hormone panels rather than a fixed schedule. This is a matter of clinical judgment among specialists managing individual cases, not a validated protocol, and it should be presented to families as such.

Monitoring: more frequent, not less, than adult protocols

Because there is no adolescent trial data to define a safety margin, monitoring in this age group should be more comprehensive than what an adult on enclomiphene would typically receive, not the same or less.

At baseline, a reasonable panel includes complete blood count, comprehensive metabolic panel, two morning total testosterone measurements, LH, FSH, estradiol, SHBG, prolactin, TSH and free T4 (to rule out thyroid causes of delayed puberty), a bone-age radiograph, documented Tanner stage, height and weight, and a validated adolescent depression screening tool. Repeat hormone panels at roughly six weeks and three months, with bone-age imaging repeated no less often than every three to six months, are the practical minimum given the growth-plate concern discussed above. Any bone-age advance the treating pediatric endocrinologist considers clinically significant for that patient, any new or worsening depressive symptoms, any new visual symptoms, or testosterone rising well above the pre-set target should trigger reassessment and likely discontinuation.

Compounding and regulatory status

No FDA-approved enclomiphene citrate product exists as of mid-2025; the FDA reviewed but did not approve the original manufacturer's new drug application [3]. Every dose available in the United States comes from a compounding pharmacy operating under the 503A (patient-specific) or 503B (outsourcing facility) frameworks the FDA describes in its general compounding guidance [12]. Compounded products are not required to undergo the same premarket testing, batch consistency verification, or postmarketing surveillance as an FDA-approved drug. The FDA's public materials describe the general risks of compounded drugs, including variability between pharmacies and batches, but this article did not locate a specific, dated potency-variance figure for compounded clomiphene-class products, and no such number should be presented as established. Families and prescribers should verify that any compounded product comes from a 503B-registered outsourcing facility and should ask for a current Certificate of Analysis for the specific lot dispensed; the FDA maintains a registered outsourcing facility list for this purpose [12].

Informed consent: what the conversation needs to include

Prescribing enclomiphene to a patient aged 12 to 17 should involve informed consent from a parent or guardian and assent from the adolescent patient, documented in the chart. The conversation should state plainly that enclomiphene has never been studied in a randomized trial in this age group; that the adult evidence suggesting it raises testosterone and preserves sperm counts comes entirely from grown men [2]; that the drug is available only as a compounded product with less regulatory oversight than an FDA-approved drug [3, 12]; and that the specific adolescent risks under discussion, growth-plate acceleration, disruption of a still-maturing hormonal axis, and mood effects, are plausible based on the drug's mechanism but have not been measured directly in this population. The American Academy of Pediatrics' guidance on off-label prescribing in children calls for explicit discussion of a treatment's off-label status as part of standard pediatric informed consent, and that discussion should be documented [13].

When specialist co-management is not optional

Given the irreversibility of the risks under discussion, premature growth-plate closure cannot be undone, and axis disruption during a maturation window is not well studied enough to promise reversibility, solo management by a primary care clinician or a telehealth-only prescriber is not appropriate. A board-certified pediatric endocrinologist should evaluate the patient before any prescription and should co-manage treatment throughout. If fertility preservation is the stated reason for choosing enclomiphene over testosterone, a reproductive urologist or pediatric-experienced reproductive endocrinologist should also be involved. If the patient has any personal history of depression, anxiety, or another mental health condition, a baseline psychiatric evaluation before starting is a reasonable precaution, consistent with the general pediatric principle of added caution when introducing a hormone-modulating drug in a patient with prior mental health vulnerability; this is a matter of clinical judgment rather than a specific guideline requirement for enclomiphene.

Evidence boundary: what is established, what is plausible, what is unknown

Established: Enclomiphene has no FDA approval in any age group and is compounded-only in the US market as of mid-2025 [3]. In adult men with secondary hypogonadism, it raises testosterone and, unlike testosterone replacement, preserves sperm production over the short term studied [2]. Estrogen signaling drives epiphyseal fusion generally [5]. No trial has enrolled anyone aged 12 to 17.

Plausible but unproven: That the same testosterone-and-sperm-preservation pattern seen in adult men would hold in adolescents with open growth plates. That bone-age acceleration is a real risk with enclomiphene specifically in this age group, based on its mechanism, even though direct measurement in adolescents does not exist. That adolescents experience mood-related adverse effects at different rates than adults.

Not established: Any specific adolescent dosing regimen. Any specific numeric threshold (estradiol level, bone-age advance, compounded potency variance) that predicts harm in this population. Whether axis effects reverse cleanly after stopping the drug in a still-maturing adolescent, as they appear to in adults.

Frequently asked questions

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. Adult guideline; does not address enclomiphene or adolescents. https://pubmed.ncbi.nlm.nih.gov/29562364/
2. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone. BJU Int. 2016. Adult men only. https://pubmed.ncbi.nlm.nih.gov/26496621/
3. U.S. Food and Drug Administration. NDA 022496 (enclomiphene citrate) review documents. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022496
4. Almeida M, Laurent MR, Dubois V, et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev. 2017. General mechanism reference, not adolescent enclomiphene data. https://pubmed.ncbi.nlm.nih.gov/27807202/
5. Harrington J, Palmert MR. Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests. J Clin Endocrinol Metab. 2012. https://pubmed.ncbi.nlm.nih.gov/22745245/
6. Blakemore SJ, Choudhury S. Development of the adolescent brain: implications for executive function and social cognition. J Child Psychol Psychiatry. 2006. https://pubmed.ncbi.nlm.nih.gov/16492261/
7. U.S. Food and Drug Administration. Clomid (clomiphene citrate) prescribing information. Racemic parent compound label; enclomiphene has no FDA label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016131s026lbl.pdf
8. Rohayem J, Lubrano C, Nieschlag E, Kliesch S. Testicular function and clinical characteristics of patients with idiopathic hypogonadotropic hypogonadism with and without anosmia. Andrology. 2021. Observational data on gonadotropin-treated hypogonadotropic males, not enclomiphene-specific. https://pubmed.ncbi.nlm.nih.gov/33090709/
9. U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. General regulatory background; no adolescent- or enclomiphene-specific potency data. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
10. American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. Pediatrics. 2014. https://pubmed.ncbi.nlm.nih.gov/24567009/